Literature DB >> 32889041

Cerebrospinal Fluid Metabolomic Profiles Associated With Fatigue During Treatment for Pediatric Acute Lymphoblastic Leukemia.

Austin L Brown1, Pagna Sok2, Olga Taylor2, John P Woodhouse2, M Brooke Bernhardt2, Kimberly P Raghubar2, Lisa S Kahalley2, Philip J Lupo2, Marilyn J Hockenberry2, Michael E Scheurer2.   

Abstract

CONTEXT: Cancer-related fatigue (CRF) is one of the most distressing and persistent symptoms reported during pediatric acute lymphoblastic leukemia (ALL) therapy; however, information on the pathways underlying CRF severity is limited.
OBJECTIVES: We conducted global metabolomics profiling of cerebrospinal fluid (CSF) samples to provide insight into the underlying mechanisms of CRF.
METHODS: Fatigue in pediatric ALL patients (2012-2017) was assessed during postinduction therapy approximately six months after diagnosis. Postinduction CSF was collected from 171 participants, comprising discovery (n = 86) and replication (n = 85) cohorts. We also conducted secondary validation using diagnostic CSF from 48 replication cohort participants. CSF metabolomic profiling was performed using gas chromatography-mass spectrometry (MS) and liquid chromatography-MS/MS. Kendall's rank correlation was used to evaluate associations between metabolite abundance and CRF. False discovery rate was used to account for multiple comparisons.
RESULTS: Participants were 56% males and 59% Hispanic with a mean age at diagnosis of 8.5 years. A total of 274 CSF-derived metabolites were common to the discovery and replication cohorts. Eight metabolites were significantly associated with fatigue in the discovery cohort (P < 0.05), of which three were significant in the replication cohort, including false discovery rate-corrected associations with gamma-glutamylglutamine (Pcombined = 6.2E-6) and asparagine (Pcombined = 3.5E-4). Notably, the abundance of gamma-glutamylglutamine in diagnostic CSF samples was also significantly associated with fatigue (P = 0.0062).
CONCLUSION: The metabolites identified in our assessment have been implicated in neurotransmitter transportation and glutathione recycling, suggesting that glutamatergic pathways or oxidative stress may contribute to ALL-associated CRF. This information could inform targeted therapies for reducing CRF in at-risk individuals.
Copyright © 2020 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Patient-reported symptoms; biomarkers; cancer-related fatigue; cerebrospinal fluid; metabolomics; pediatric acute lymphoblastic leukemia

Mesh:

Substances:

Year:  2020        PMID: 32889041      PMCID: PMC7914130          DOI: 10.1016/j.jpainsymman.2020.08.030

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  49 in total

1.  Effect of gamma-glutamyl transpeptidase inhibitors on the transport of glutamate into neuronal and glial primary cultures.

Authors:  B Jankásková; V Lisý; F Stastný
Journal:  Int J Dev Neurosci       Date:  1992-06       Impact factor: 2.457

2.  NCCN Clinical Practice Guidelines Cancer-related fatigue.

Authors:  Ann M Berger; Amy Pickar Abernethy; Ashley Atkinson; Andrea M Barsevick; William S Breitbart; David Cella; Bernadine Cimprich; Charles Cleeland; Mario A Eisenberger; Carmen P Escalante; Paul B Jacobsen; Phyllis Kaldor; Jennifer A Ligibel; Barbara A Murphy; Tracey O'Connor; William F Pirl; Eve Rodler; Hope S Rugo; Jay Thomas; Lynne I Wagner
Journal:  J Natl Compr Canc Netw       Date:  2010-08       Impact factor: 11.908

3.  Changes in the activity of gamma-glutamyl transpeptidase induced by kainic acid and surgical lesions of the hippocampal formation in young rats.

Authors:  F Stastný; F Rothe; W Schmidt; G Wolf; G Keilhoff; V Lisý
Journal:  Brain Res       Date:  1988-10-11       Impact factor: 3.252

4.  Psychometric and clinical assessment of the 13-item reduced version of the fatigue scale-adolescent instrument.

Authors:  Belinda N Mandrell; Jie Yang; Mary C Hooke; Chong Wang; Jami S Gattuso; Marilyn Hockenberry; Heather Jones; Sue Zupanec; Pamela S Hinds
Journal:  J Pediatr Oncol Nurs       Date:  2011-08-15       Impact factor: 1.636

5.  2000 CDC Growth Charts for the United States: methods and development.

Authors:  Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson
Journal:  Vital Health Stat 11       Date:  2002-05

6.  Symptom Trajectories in Children Receiving Treatment for Leukemia: A Latent Class Growth Analysis With Multitrajectory Modeling.

Authors:  Marilyn J Hockenberry; Mary C Hooke; Cheryl Rodgers; Olga Taylor; Kari M Koerner; Pauline Mitby; Ida Moore; Michael E Scheurer; Wei Pan
Journal:  J Pain Symptom Manage       Date:  2017-04-20       Impact factor: 3.612

7.  Chronic fatigue in adult survivors of childhood cancer: associated symptoms, neuroendocrine markers, and autonomic cardiovascular responses.

Authors:  Bernward Zeller; Ellen Ruud; Jon Havard Loge; Adriani Kanellopoulos; Hanne Hamre; Kristin Godang; Vegard Bruun Wyller
Journal:  Psychosomatics       Date:  2013-12-08       Impact factor: 2.386

8.  Hematologic and urinary excretion anomalies in patients with chronic fatigue syndrome.

Authors:  Suzanne H Niblett; Katrina E King; R Hugh Dunstan; Phillip Clifton-Bligh; Leigh A Hoskin; Timothy K Roberts; Greg R Fulcher; Neil R McGregor; Julie C Dunsmore; Henry L Butt; Iven Klineberg; T B Rothkirch
Journal:  Exp Biol Med (Maywood)       Date:  2007-09

9.  Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia.

Authors:  Jeremy M Schraw; Jacob J Junco; Austin L Brown; Michael E Scheurer; Karen R Rabin; Philip J Lupo
Journal:  EBioMedicine       Date:  2019-10-17       Impact factor: 8.143

10.  Metabolic analysis of amino acids and vitamin B6 pathways in lymphoma survivors with cancer related chronic fatigue.

Authors:  Alexander Fosså; Knut Halvor Smeland; Øystein Fluge; Karl Johan Tronstad; Jon Håvard Loge; Øivind Midttun; Per Magne Ueland; Cecilie Essholt Kiserud
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

View more
  6 in total

1.  The predictive trifecta? Fatigue, pain, and anxiety severity forecast the suffering profile of children with cancer.

Authors:  Meaghann S Weaver; Jichuan Wang; Katie A Greenzang; Molly McFatrich; Pamela S Hinds
Journal:  Support Care Cancer       Date:  2021-10-18       Impact factor: 3.603

2.  Metabolites Associated With Fatigue and Physical Activity in Childhood Cancer.

Authors:  Janice S Withycombe; Ronald Eldridge; Yan Jin; Haiwai Gu; Sharon M Castellino; Dorothy D Sears
Journal:  Biol Res Nurs       Date:  2022-04-25       Impact factor: 2.318

Review 3.  Using primary teeth and archived dried spots for exposomic studies in children: Exploring new paths in the environmental epidemiology of pediatric cancer.

Authors:  Philip J Lupo; Lauren M Petrick; Thanh T Hoang; Amanda E Janitz; Erin L Marcotte; Jeremy M Schraw; Manish Arora; Michael E Scheurer
Journal:  Bioessays       Date:  2021-06-09       Impact factor: 4.653

Review 4.  Cerebrospinal Fluid Biomarkers in Childhood Leukemias.

Authors:  Chrysanthy Ikonomidou
Journal:  Cancers (Basel)       Date:  2021-01-24       Impact factor: 6.639

Review 5.  A Molecular Approach to Understanding the Role of Diet in Cancer-Related Fatigue: Challenges and Future Opportunities.

Authors:  Sylvia L Crowder; Mary C Playdon; Lisa M Gudenkauf; Jennifer Ose; Biljana Gigic; Leigh Greathouse; Anita R Peoples; Alix G Sleight; Heather S L Jim; Jane C Figueiredo
Journal:  Nutrients       Date:  2022-04-02       Impact factor: 6.706

6.  Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia.

Authors:  Jeremy M Schraw; J P Woodhouse; Melanie B Bernhardt; Olga A Taylor; Terzah M Horton; Michael E Scheurer; M Fatih Okcu; Karen R Rabin; Philip J Lupo; Austin L Brown
Journal:  Sci Rep       Date:  2021-10-04       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.